Role of islet amyloid in type 2 diabetes mellitus: Consequence or cause?

Molecular and Cellular Endocrinology

Volumn 197, Issue 1-2, 2002, Pages 205-212

  Höppener, Jo W M ^a,b   Nieuwenhuis, Maria G ^a   Vroom, Thea M ^a   Ahrén, Bo ^c   Lips, Cees J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LUND UNIVERSITY   (Sweden)

Author keywords

cell failure; Diabetogenic factor; Islet amyloid; Islet amyloid polypeptide; Transgenic mouse models; Type 2 diabetes

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; GLYCOSAMINOGLYCAN; INSULIN; METFORMIN; SERUM AMYLOID P; AMYLOID;

AMYLOIDOSIS; BIOACCUMULATION; BIOLOGICAL MODEL; CAT; CLINICAL TRIAL; DIABETOGENESIS; DRUG EFFECT; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; MONKEY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; TRANSGENIC MOUSE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; PANCREAS ISLET; PROTEIN SECONDARY STRUCTURE; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; AMYLOID; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; ISLETS OF LANGERHANS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ALIGNMENT;

EID: 0037195537     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(02)00266-6     Document Type: Review

References (56)

1. Ahrén B., Oosterwijk C., Lips C.J.M., Höppener J.W.M. Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secetion and glucose elimination after gastric glucose gavage in mice. Diabetologia. 41:1998;1374-1380.
2. Booth D.R., Sunde M., Bellotti V., et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature. 385:1997;787-793.
3. Botto M., Hawkins P.N., Bickerstaff M.C., et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat. Med. 3:1997;855-859.
4. Cook J.T.E., Patel P.P., Clark A., et al. Non-linkage of the islet amyloid polypeptide gene with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 34:1991;103-108.
5. Cooper G.J.S., Willis A.C., Clark A., et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. USA. 84:1987;8628-8632.
6. Cooper G.J.S., Leighton B., Dimitriadis G.D., et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc. Natl. Acad. Sci. USA. 85:1988;7763-7766.
7. Couce M., Kane L.A., O'Brien T.D., et al. Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes. 45:1996;1094-1101.
8. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr. Rev. 19:1998;477-490.
9. Gebre-Medhin S., Mulder H., Pekny M., et al. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem. Biophys. Res. Commun. 250:1998;271-277.
10. German M.S., Moss L.G., Wang J.H., Rutter W.J. The insulin and islet amyloid polypeptide genes contain similar cell-specific promoter elements that bind identical beta-cell nuclear complexes. Mol. Cell. Biol. 12:1992;1777-1788.
11. Gillmore J.D., Hawkins P.N., Pepys M.B. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br. J. Haematol. 99:1997;245-256.
12. Glenner G.G. Amyloid deposits and amyloidosis - the β-fibrilloses. N. Engl. J. Med. 303:1980;1283-1292.
13. Harris M.I., Flegel K.M., Cowie C.C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. Diabetes Care. 21:1998;518-524.
14. Hoenig M., Hall G., Ferguson D.C., et al. A feline model of experimentally induced islet amyloidosis. Am. J. Pathol. 157:2000;2143-2150.
15. Höppener J.W.M., Verbeek J.S., De Koning E.J.P., et al. Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycemia or hyperinsulinemia. Diabetologia. 36:1993;1258-1265.
16. Höppener J.W.M., Oosterwijk C., Van Hulst K.L., et al. Molecular physiology of the islet amyloid polypeptide (IAPP)/amylin gene in man, rat, and transgenic mice. J. Cell. Biochem. Suppl. 55:1994;39-53.
17. Höppener J.W.M., Oosterwijk C., Nieuwenhuis M.G., et al. Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a transgenic mouse model. Diabetologia. 42:1999;427-434.
18. Höppener J.W.M.,. Ahrén B., Lips C.J.M. Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med. 343:2000a;411-419.
19. Höppener J.W.M., Nieuwenhuis M.G., Vroom T.h.M., Lips C.J.M. Eilandjesamyloid en diabetes mellitus type 2. Ned. Tijdschr. Geneeskd. 42:2000b;1995-2000.
20. Höppener, J.W.M., Oosterwijk, C., Jiménez-Chillarón, J.C. et al. Islet Amyloid and Glucose Intolerance in High-fat Fed Mice Transgenic for Human Islet Amyloid Polypeptide. To be submitted.
21. Howard C.F. Jr. Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia. 29:1986;301-306.
22. Inzucchi S.E., Maggs D.G., Spollett G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 338:1998;872-876.
23. Janson J., Soeller W.C., Roche P.C., et al. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. USA. 93:1996;7283-7288.
24. Janson J., Ashley R.H., Harrison D., et al. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes. 48:1999;491-498.
25. Janus C., Pearson J., McLaurin J.A., et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
26. Johnson K.H., O'Brien T.D., Jordan K., Westermark P. Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am. J. Pathol. 135:1989;245-250.
27. Kahn B.B. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell. 92:1998;593-596.
28. Kahn S.E. The importance of beta-cell failure in the development and progression of type 2 diabetes. J. Clin. Endocrinol. Metab. 86:2001;4047-4058.
29. Kahn S.E., Andrikopoulos S., Verchere C.B. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes. 48:1999;241-253.
30. Karlsson E. IAPP as a regulator of glucose homeostasis and pancreatic hormone secretion. Int. J. Mol. Med. 3:1999;577-584.
31. Kisilevsky R. Anti-amyloid drugs. Potential in the treatment of disease associated with aging. Drugs Aging. 8:1996;75-83.
32. Larsson H., Ahrén B. Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia. 39:1996;1099-1107.
33. Lindström T., Leckström A., Westermark P., Arnqvist H.J. Effect of insulin treatment on circulating islet amyloid polypeptide in patients with NIDDM. Diab. Med. 14:1997;472-476.
34. Lorenzo A., Razzaboni B., Weir G.C., Yankner B.A. Pancreatic islet cell toxicity of amylin associated with type 2 diabetes mellitus. Nature. 368:1994;756-760.
35. Mokdad A.H., et al. Diabetes trends in the US: 1990-1998. Diabetes Care. 23:2000;1278-1283.
36. Morgan D., Diamond D.M., Gottschall P.E., et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
37. Mosselman S., Höppener J.W.M., Zandberg J., et al. Islet amyloid polypeptide: identification and chromosomal localization of the human gene. FEBS Lett. 239:1988;227-232.
38. Nishi M., Bell G.I., Steiner D.F. Islet amyloid polypeptide (amylin): no evidence of an abnormal precursor sequence in 25 type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 33:1990;628-630.
39. Novials A., Rojas I., Franco C., et al. A novel mutation in islet amyloid polypeptide (IAPP) gene promoter is associated with type II diabetes mellitus. Diabetologia. 44:2001;1064-1065.
40. Opie E.L. The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans. J. Exp. Med. 5:1901;527-540.
41. Pardes H., et al. Effects of medical research on health care and economy. Science. 283:1999;36-37.
42. Porte D. Jr, Kahn S.E. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes. 50:(Suppl. 1):2001;S160-S163.
43. Rachman J., Payne M.J., Levy J.C., et al. Changes in amylin and amylin-like peptide concentrations and β-cell function in response to sulfonurea or insulin therapy in NIDDM. Diabetes Care. 21:1998;810-815.
44. Sakagashira S., Sanke T., Hanabusa T., et al. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes. 45:1996;1279-1281.
45. Sakagashira S., Hiddinga H.J., Wateishi K., et al. S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wildtype amylin. Am. J. Pathol. 157:2000;2101-2109.
46. Schenk D., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
47. Soeller W.C., Janson J., Hart S.E., et al. Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. Diabetes. 47:1998;743-750.
48. Soto C., Sigurdsson E.M., Morelli L., et al. β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat. Med. 4:1998;822-826.
49. Turner R. The UK prospective diabetes study; a review. Diabetes Care. 21:(Suppl. 3):1998;C35-C38.
50. Verchere C.B., Dálessio D.A., Palmiter R.D., et al. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc. Natl. Acad. Sci. USA. 93:1996;3492-3496.
51. Virchow R. Virchows Arch. Pathol. Anat. Physiol. 6:1854;135-137.
52. Westermark P. Amyloid and polypeptide hormones: what is their relationship? Amyloid: Int. J. Exp. Clin. Invest. 1:1994;47-60.
53. Westermark P., Wernstedt C., Wilander E., Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibrilprotein in the endocrine pancreas. Biochem. Biophys. Res. Commun. 140:1986;827-831.
54. Westermark P., Wernstedt C., Wilander E., et al. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. USA. 84:1987;3881-3885.
55. Westermark P., Engström U., Johnson K.H., et al. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA. 87:1990;5036-5040.
56. Zapecka-Dubno B., Czyzyk A., Dworak A., Bak M.I. Treatment with metformin in NIDDM patients lowers plasma amylin level. Diabetologia. 40:(Suppl. 1):1997;A316.